{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:07:35Z","timestamp":1787933255697,"version":"build-2784847793"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005624","name":"Medizinischen Hochschule Hannover","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymthe.2024.01.034","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T03:22:27Z","timestamp":1706930547000},"page":"619-636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II"],"prefix":"10.1016","volume":"32","author":[{"given":"Sabyasachi","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatlum","family":"Rruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-476X","authenticated-orcid":false,"given":"Annita","family":"Montepeloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Dimartino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Spadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janki","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cavalca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Milazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Galy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letterio S.","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Rizzardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Vallanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4610-0870","authenticated-orcid":false,"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.01.034_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymthe.2024.01.034_bib2","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2024.01.034_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2024.01.034_bib4","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.01.034_bib5","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.034_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2024.01.034_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmg.2010.07.013","article-title":"First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS)","volume":"53","author":"Alcalde-Mart\u00edn","year":"2010","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ymthe.2024.01.034_bib8","first-page":"CD008185","article-title":"Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)","volume":"2","author":"da Silva","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.01.034_bib10","first-page":"81","article-title":"Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series","volume":"41","author":"Selvanathan","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2024.01.034_bib11","article-title":"Real world long-term outcomes in patients with mucopolysaccharidosis type II: A retrospective cohort study","volume":"29","author":"Tomita","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymthe.2024.01.034_bib12","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13052-018-0565-y","article-title":"Gene therapy for mucopolysaccharidoses: in\u00a0vivo and ex\u00a0vivo approaches","volume":"44","author":"Fraldi","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymthe.2024.01.034_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.01.034_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10059-010-0083-2","article-title":"Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2\/8 vector-mediated gene therapy","volume":"30","author":"Jung","year":"2010","journal-title":"Mol. Cells"},{"key":"10.1016\/j.ymthe.2024.01.034_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.01.034_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.01.034_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.01.034_bib19","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.01.034_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.01.034_bib21","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.034_bib22","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.01.034_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/hum.2016.068","article-title":"Preclinical Testing of the Safety and Tolerability of Lentiviral Vector-Mediated Above-Normal Alpha-L-Iduronidase Expression in Murine and Human Hematopoietic Cells Using Toxicology and Biodistribution Good Laboratory Practice Studies","volume":"27","author":"Visigalli","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/hum.2020.135","article-title":"Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of","volume":"32","author":"Chanut","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib25","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2024.01.034_bib26","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1182\/blood-2009-10-249326","article-title":"Engraftment of human hematopoietic stem cells is more efficient in female NOD\/SCID\/IL-2Rgc-null recipients","volume":"115","author":"Notta","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.034_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1182\/blood-2010-02-271841","article-title":"Comparison of human cord blood engraftment between immunocompromised mouse strains","volume":"116","author":"McDermott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.034_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032712-095921","article-title":"Human hemato-lymphoid system mice: current use and future potential for medicine","volume":"31","author":"Rongvaux","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.01.034_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.38","article-title":"Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy","volume":"2","author":"Ungari","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","article-title":"Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency","volume":"9","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.omtm.2018.10.014","article-title":"Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling \u03b2AS3 Globin for Gene Therapy for Sickle Cell Disease","volume":"11","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.omtm.2018.09.001","article-title":"Multiple Integrated Non-clinical Studies Predict the Safety of Lentivirus-Mediated Gene Therapy for \u03b2-Thalassemia","volume":"11","author":"Lidonnici","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.01.034_bib34","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2024.01.034_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1750-3639.2010.00394.x","article-title":"Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy","volume":"20","author":"Cartier","year":"2010","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ymthe.2024.01.034_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.01.034_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2020.06.007","article-title":"Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy","volume":"130","author":"Miwa","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2024.01.034_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtm.2020.09.012","article-title":"Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation","volume":"19","author":"Wada","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.01.034_bib39","article-title":"Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment","volume":"21","author":"D'Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.034_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management","volume":"21","author":"Sawamoto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.01.034_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2024.01.034_bib42","article-title":"Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II","author":"Wood","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib43","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/hum.2021.089","article-title":"Preferential Expansion of Human CD34(+)CD133(+)CD90(+) Hematopoietic Stem Cells Enhances Gene-Modified Cell Frequency for Gene Therapy","volume":"33","author":"Christopher","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.stem.2019.09.008","article-title":"Sphingolipid Modulation Activates Proteostasis Programs to Govern Human Hematopoietic Stem Cell Self-Renewal","volume":"25","author":"Xie","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.01.034_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2024.01.034_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172435","article-title":"Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II","volume":"12","author":"Gleitz","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.01.034_bib47","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood-2005-08-024976","article-title":"Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity","volume":"108","author":"Modlich","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.01.034_bib48","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2009.179","article-title":"Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors","volume":"17","author":"Modlich","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/gt.2011.117","article-title":"Epidermal growth factor improves lentivirus vector gene transfer into primary mouse hepatocytes","volume":"19","author":"Rothe","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib50","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1016\/j.ymthe.2021.06.017","article-title":"Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning","volume":"29","author":"Schwarzer","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.01.034_bib51","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2004-5-10-r80","article-title":"Bioconductor: open software development for computational biology and bioinformatics","volume":"5","author":"Gentleman","year":"2004","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2024.01.034_bib52","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.01.034_bib53","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments","volume":"28","author":"Leek","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2024.01.034_bib54","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:10:21Z","timestamp":1761502221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1525001624000340"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.034","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}